Welcome to our dedicated page for Mesoblast SEC filings (Ticker: MEOBF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Mesoblast Limited (MEOBF) SEC filings page provides access to the company’s U.S. regulatory disclosures as a foreign private issuer incorporated in Australia. Mesoblast Limited files annual reports under cover of Form 20-F and furnishes current information on Form 6-K pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Mesoblast’s Form 6-K submissions typically attach documents first filed with the Australian Securities Exchange (ASX). These include new issue announcements, notifications of issue, conversion or payment up of unquoted equity securities (Appendix 3G), applications for quotation of securities (Appendix 2A), notifications of cessation of securities (Appendix 3H), proposed issues of securities (Appendix 3B), and change of director’s interest notices (Appendix 3Y), as well as press and news release announcements.
Through this page, users can review how Mesoblast Limited reports on equity securities activity, including issuances, proposed issues, cessations, and applications for quotation, and how it discloses changes in directors’ holdings in its securities. These filings are relevant for investors tracking capital structure developments, director share transactions, and formal corporate announcements.
Stock Titan enhances these filings with AI-powered tools that help explain the structure and contents of lengthy documents. While the original Form 20-F and 6-K texts remain the authoritative sources, AI summaries can highlight key sections, such as equity changes or director interest updates, and make it easier to navigate the exhibits attached from the ASX. Real-time updates from EDGAR ensure that new Mesoblast Limited filings appear promptly, giving users a structured way to follow the company’s regulatory history.
Mesoblast Limited has filed a Form F-3 to register up to 5,000,000 ordinary shares, represented by 500,000 American Depositary Shares (ADSs), for resale by existing shareholders. These shares are issuable upon exercise of warrants granted in a December 2025 private placement. The ADSs trade on Nasdaq under “MESO” and each ADS equals 10 ordinary shares.
The selling shareholders, including Dr. Gregory George and Dr. William Gueck, will receive all proceeds from any ADS resales, while Mesoblast will only receive US$16.25 per ADS when warrants are exercised. The warrants cover up to 5,000,000 ordinary shares, have a four‑year term, and 3,000,000 of them become exercisable only if Mesoblast elects to issue up to US$50 million of subordinated unsecured convertible notes under related subscription agreements. Ordinary shares outstanding after the offering would be 1,290,802,187.
Mesoblast Limited submitted a foreign issuer report to the U.S. SEC for December 2025. The company notes that on December 23, 2025 it lodged with the Australian Securities Exchange a new issue announcement and a change of director’s interest notice (Appendix 3Y), which is attached as an exhibit to this report and incorporated by reference. The filing is administrative in nature and centers on disclosure of director shareholding changes and related new issue details rather than operating or financial results.
Mesoblast Limited submitted a foreign issuer report describing an action first disclosed on the Australian Securities Exchange. On December 17, 2025, the company lodged an Appendix 3G with the ASX, which relates to a new issue announcement and the issue, conversion or payment up of unquoted equity securities. This Appendix 3G document is attached to the report as an exhibit and is incorporated by reference for further details.
Mesoblast Limited submitted a Form 6-K to provide U.S. investors with materials it filed with the Australian Securities Exchange. The report states that on November 25, 2025, the company lodged the Chair’s Annual General Meeting address and the CEO’s presentation to the Annual General Meeting, which are included as Exhibits 99.1 and 99.2. It also includes a press release dated the same day as Exhibit 99.3. These documents are incorporated by reference, making the Australian-market communications available to investors following Mesoblast’s U.S. listing.